


IN THE CLAIMS

Please amend the claims as follows:

1. [Amended] A compound of formula (I):



wherein X is O;

n is an integer from 0 to 3;

R₅ is C₁₋₁₀ alkyl, C₃₋₈ alkenyl, C₃₋₈ cycloalkyl, (C₃₋₈ cycloalkyl) C₁₋₆ alkyl, (phenyl)C₁₋₆ alkyl, (phenyl)C₃₋₈ alkenyl, or (C₁₋₈ alkylcarbonyl)C₁₋₈ alkyl;

one of R₁, R₂, and R₃ is W, wherein one of the remaining two is selected from H and halogen, and the third being hydrogen;

R₆ is independently selected from hydrogen, C₁₋₈ alkyl, C₁₋₆ alkoxy, C₂₋₈ alkenyl, C₃₋₇ cycloalkyl, (C₃₋₇ cycloalkyl)C₁₋₆ alkylene, C₂₋₁₅ heterocyclyl, and (C₂₋₇ heterocyclyl)C₁₋₆ alkylene;

R₇ is H, hydroxyl, halo, C₂₋₆ alkoxy or absent where the carbon linking L₆ and L₇ (or bonded to R₆) participates in a double bond;

each of R₈ and R₉ is independently selected from hydrogen, C₁₋₆ alkoxy, C₁₋₈ alkyl, C₃₋₈ alkenyl, C₃₋₇ cycloalkyl, (C₃₋₇ cycloalkyl)C₁₋₆ alkylene, C₂₋₁₅ heterocyclyl, phenyl, (C₂₋₁₅ heterocyclyl)C₁₋₆ alkylene, and (phenyl) C₁₋₆ alkylene;

R₁₀ is H, C₁₋₈ alkyl, C₃₋₈ alkenyl, C₃₋₇ cycloalkyl, (C₃₋₇ cycloalkyl)C₁₋₆ alkylene, (C₂₋₁₅ heterocyclyl)C₁₋₆ alkylene, or (phenyl) C₁₋₆ alkylene;

W is piperazinyl or morpholinyl;

wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C₁₋₃ alkyl;

or a pharmaceutically acceptable salt, ester, or amide thereof.

2. A compound of claim 1, wherein R₅ is C₁₋₅ alkyl, C₃₋₄ alkenyl, C₃₋₆ cycloalkyl, (C₃₋₆ cycloalkyl) C₁alkylene, (phenyl)C₁₋₃ alkylene, or (phenyl)C₃₋₄ alkenylene.

3. A compound of claim 2, wherein R₅ is branched C₃₋₅ alkyl, C₃₋₆ cycloalkyl, and (C₃₋₆ cycloalkyl) C₁ alkylene.

4. (Amended) A compound of claim 1, wherein one of R₂ and R₃ is W.

5. (Amended) A compound of claim 4, wherein R₂ is W.

6. (Amended) A compound of claim 4, wherein R₃ is W.

15. (Amended) A compound of claim 1, wherein W is a substituted or unsubstituted N-morpholinyl.

20. A compound of claim 18, wherein R₅ is C₁₋₅ alkyl, C₃₋₄ alkenyl, C₃₋₆ cycloalkyl, (C₃₋₆ cycloalkyl) C₁alkylene, (phenyl)C₁₋₃ alkylene, or (phenyl)C₃₋₄ alkenylene.

21. A compound of claim 1, wherein n is 0 or 1.

22. A compound of claim 21, wherein n is 0.

A4

33. (Amended) A compound of claim 1, wherein R_5 is C_{1-5} alkyl, C_{3-4} alkenyl, C_{3-6} cycloalkyl, (C_{3-6} cycloalkyl) C_1 alkylene, (phenyl) C_{1-3} alkylene, or (phenyl) C_{3-4} alkenylene.

A5

36. (Amended) A compound of claim 1, wherein one of R_2 and R_3 is W.

37. A compound of claim 21, wherein R_5 is branched C_{3-5} alkyl.

38. A compound of claim 21, wherein R_5 is isopropyl or cyclopentyl.

43. A compound of claim 1, selected from 1-Isopropyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-piperazine, 1-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-piperazine, and 1-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-piperazine.

A6

44. (Amended) A compound of claim 1, selected from 4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine, 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-piperazine, 4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine, 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-phenyl-piperazine, 1-Benzyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperazine, 4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine, 4-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-morpholine, 4-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-morpholine, 4-[4-(1-Propyl-piperidin-4-yloxy)-benzyl]-morpholine.

45. (Amended) A compound of claim 1, selected from 4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine, 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-piperazine, 4-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-morpholine, 4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine, 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-phenyl-piperazine, 1-Benzyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperazine, 4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine, 4-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-morpholine, and 4-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-morpholine.

A7

47. (Amended) A compound of claim 1 or 21, isotopically labelled to be detectable by PET or SPECT.

48. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

A8

49. (Amended) A method of inhibiting histamine H_3 receptor activity in a subject, comprising administering an effective amount of a compound of

claim 1, 21, 43, or 45 to a subject in need of such inhibition of histamine H₃ receptor activity.

- A⁸
cont.
50. (Amended) A method of treating a subject having a disease or condition modulated by histamine H₃ receptor activity, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, 21, 43, or 45.
51. (Amended) A method of claim 50, wherein said disease or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.
-

- A⁹
56. (Amended) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 21, or 45.
57. (Amended) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 21, or 45.
58. (Amended) A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment, cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 21, or 45.
59. (Amended) A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 21, or 45.
-